Michael Lotze

Michael Lotze

Company: Nurix Therapeutics

Job title: Chief Cell Therapy Officer

Seminars:

Combining TIL with Small Molecule Inhibitors to Enhance T – Cell Expansion & Phenotypes 2:00 pm

• Expanding the scope of indications to include gynaecological malignancies by combining with small molecule inhibitors • Applying targeted protein modulation to adoptive cell therapy • Inhibiting CBL-B to stimulate IL-2 secretion, reduce T cell exhaustion and improve clinical outcomesRead more

day: Day One

Industry Leaders’ Fireside Chat – Accelerating the Potential of Adoptive T-Cell Therapy to Drive Toward Approved Cell Therapies in Solid Tumors: Discussing the Past, Present & Future for TIL 9:00 am

TIL therapies have come a long way since the pioneering work of Dr Rosenberg in the late 80s and the opportunity TIL provides to improve and expand on current immunotherapeutic treatments holds a great deal of promise. Key themes and questions to be explored include: •Discussing the key lessons learned from past developments to apply…Read more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.